Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.

Zhenggang Ren, Stephen L. Chan, Aibing Xu et al.|Journal of Clinical Oncology|2023

Cited by 25